Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.

Joris van de Haar Joanne M Mankor Karlijn Hummelink Kim Monkhorst Egbert F Smit Lodewyk F A Wessels Edwin Cuppen Joachim G J V Aerts Emile E Voest

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

The unexpected ICB responses in patients carrying resistance biomarkers in STK11, KEAP1, and EGFR were almost exclusively observed in patients with a high TMB. Considering these alterations in context, the TMB offered a highly specific combinatorial biomarker strategy for limiting overtreatment in NSCLC.

Keyphrases

small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
peritoneal dialysis
epidermal growth factor receptor
tyrosine kinase
copy number
patient reported outcomes
brain metastases